Close Menu

NEW YORK – Tempus said on Wednesday that it will collaborate with A2 Biotherapeutics to develop a companion diagnostic test for A2's loss of heterozygosity-targeted cell therapy platform, Tmod.

According to Tempus, the partnership could also expand in the future to include development of additional CDx tests for A2’s other clinical development programs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.